Ranibizumab
ApprovedWithdrawn 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema
Conditions
Diabetic Macular Edema
Trial Timeline
Mar 1, 2014 → Jul 1, 2015
NCT ID
NCT02055911About Ranibizumab
Ranibizumab is a approved stage product being developed by Novartis for Diabetic Macular Edema. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02055911. Target conditions include Diabetic Macular Edema.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Macular Edema were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04464694 | Approved | UNKNOWN |
| NCT02953938 | Approved | Completed |
| NCT02976194 | Approved | UNKNOWN |
| NCT02843490 | Approved | Completed |
| NCT02640664 | Phase 3 | Completed |
| NCT02707575 | Pre-clinical | Completed |
| NCT02634970 | Approved | Withdrawn |
| NCT02375971 | Phase 3 | Completed |
| NCT02329132 | Pre-clinical | Completed |
| NCT02161575 | Approved | Completed |
| NCT02034006 | Phase 3 | Completed |
| NCT02059772 | Approved | UNKNOWN |
| NCT01986907 | Approved | Completed |
| NCT02055911 | Approved | Withdrawn |
| NCT02478515 | Approved | Completed |
| NCT01972789 | Approved | Completed |
| NCT01846299 | Phase 3 | Completed |
| NCT01908816 | Phase 3 | Completed |
| NCT01840410 | Phase 3 | Completed |
| NCT01780935 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetic Macular Edema